Randomized Trial of [131I] Metuximab in Treatment of Hepatocellular Carcinoma After Percutaneous Radiofrequency Ablation
Mené en Chine sur 127 patients atteints d'un carcinome hépatocellulaire, cet essai évalue, du point de vue des taux de récidive à 1 et 2 ans, l'intérêt du métuximab-I131 après une ablation percutanée par radiofréquence
To assess the efficacy of combining radioimmunoconjugate [131I] metuximab with radiofrequency ablation (RFA) in hepatocellular carcinoma (HCC) treatment compared with RFA alone, a single-center randomized controlled trial was conducted on 127 patients with Barcelona Clinic Liver Cancer staging system (BCLC) classifications of 0–B stage. Patients received either RFA followed by [131I] metuximab (n = 62) or RFA alone (n = 65). The primary outcome was overall tumor recurrence. Statistical tests were two-sided. The one- and two-year recurrence rates in the combination group were 31.8% and 58.5%, whereas those in the RFA group were 56.3% and 70.9%, respectively. The median time to overall tumor recurrence was 17 months in the combination group and 10 months in the RFA group (P = .03). The RFA-[131I] metuximab treatment showed a greater antirecurrence benefit than RFA in the metuximab target (ie, CD147)–positive subpopulation (P = .007). [131I] metuximab may yield prevention of tumor recurrence after RFA.